2026-11-13. The following slide deck was published by PepGen Inc.
PepGen is rated a Buy, after phase 2 DM1 data show 46.5% mean splicing correction, supporting a potential FDA meeting in 2H 2027.
PepGen reports solid trial data for its rare-disease candidate, pressuring rivals developing competing therapies for myotonic dystrophy type 1.
PepGen (PEPG) stock jumps as the company updates mid-stage trial for its lead asset, PGN-EDODM1, in myotonic dystrophy type 1, a rare genetic condition. Read more here.
Detailed price information for Pepgen Inc (PEPG-Q) from The Globe and Mail including charting and trades.
Detailed price information for Pepgen Inc (PEPG-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.